Sanofi-A Ventis Deutschland Gmbh

Max-Planck-Gesellschaft Zur F&#xf6;rderung Der Wissenschaften E. V.

Bayer Pharma Aktiengesellschaft

Aventis Pharma Deutschland, Gmbh

Lead Discovery Center Gmbh

Edmund Hoppe

Jonathan Rothblatt

Gisela Peraus

Axel Ullrich

Wilfried Schwab

Zoltán Greff

Bert Klebl

Axel Choidas

Heike Schauerte

Ekkehard Leberer

Niels Peter Mo Slashedller

Luc Mercken

Ralf Baumeister

Jackie Macritchie

Don Simpson

Joelle Le

Klaus Godl

Doris Hafenbradl

Gerhard Müller

Christian Hartung

Ulrike Siebers

Sylvie Dreisler

Brad Sherborne

Vladimir Savic

John Harris

Jose Bravo

Birgit Zech

Andrea Missio

Thomas Herget

Peter Habenberger

Achim Freisleben

Beatrice Felber

Ola Engkvist

Matt Cotten

Alexander Backes

Giesela Peraus

The present invention relates to 4,6-disubstituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof, the use of these derivatives as pharmaceutically active agents, especially for the prophylaxis and/or treatment of infectious diseases, including opportunistic diseases, prion diseases, immunological diseases, autoimmune diseases, bipolar and clinical disorders, cardiovascular diseases, cell proliferative diseases, diabetes, inflammation, transplant rejections, erectile dysfunction, neurodegenerative diseases and stroke, and pharmaceutical compositions containing at least one of said 4,6-di substituted aminopyrimidine derivatives and/or pharmaceutically acceptable salts thereof. Furthermore, the present invention relates to the use of said 4,6-disubstituted aminopyrimidine derivatives as inhibitors for a protein kinase and a medium comprising at least one of said 4,6-disubstituted aminopyrimidine derivatives in an immobilized form and the use of said medium for enriching, purifying and/or depleting nucleotide binding proteins which bind to the immobilized 4,6-disubstituted aminopyrimidine derivatives.

Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases

The present invention relates to an improved process for determining &#x3b3;-secretase activity and for detecting &#x3b3;-secretase, a subunit protein of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase. In particular, the present invention relates to processes for the identification of a &#x3b3;-secretase or of a cDNA which codes for a &#x3b3;-secretase, a subunit protein of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase. Another embodiment of the present invention relates to processes for the identification of substances which can inhibit the activity of &#x3b3;-secretase, or a &#x3b3;-secretase-like proteinase.

Method of screening for gamma-secretase activity

The invention relates to the identification and use of the DAF-2/IR responsive sod-3 promoter. Transgeniccontaining sod-3 reporter gene constructs are described which are useful for, among other things, the identification of genes or compounds capable of modulating the DAF-2/IR-akt pathway. Conditions are disclosed that increase or decrease the reporter activity, demonstrating the presence of either activators or inhibitors of the DAF-2/IR pathway.

[object Object]

The present invention relates to a transgenic which expresses an amyloid precursor protein (APP) or a part thereof, to the transgene itself, to the protein encoded by the transgene, and also to a process for preparing the transgenic and to its use.

Transgenic C. elegans as a model organism for investigations on Alzheimer's disease

The present invention relates to cell lines useful for the screening and identification of compounds that by modulating phosphotyrosine phosphatase activity, modulate insulin receptor type tyrosine kinase mediated signal transduction. Genetically engineered cells expressing IR in culture overcome the effect of insulin on morphology and adhesion when they are also coexpressing RPTP.alpha. or RPTP.epsilon.. Such engineered cell lines may be used to screen and identify non-toxic compounds that could elicit or modulate insulin signal transduction even in the absence of insulin.

Methods for identifying modulators of insulin receptor phosphorylation

Growing community of inventors

Krailling, Germany

Edmund Hoppe